Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.

Allen, Jeremy; Berry, Diane; Cook, Francesca; Hume, Ashley; Rouce, Rayne; Srirangam, Anirudh; Wellman, Jennifer; McCombs, Caitlin

Allen, Jeremy; Berry, Diane; Cook, Francesca; Hume, Ashley; Rouce, Rayne; Srirangam, Anirudh; Wellman, Jennifer; McCombs, Caitlin.

Afiliação

Allen J; Spark Therapeutics, Inc., Philadelphia, PA 19104, USA.
Berry D; Sarepta Therapeutics, Inc., Cambridge, MA 02142, USA.
Cook F; REGENXBIO Inc., Rockville, MD 20850, USA.
Hume A; Emerging Therapy Solutions, Bloomington, MN 55425, USA.
Rouce R; Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Srirangam A; Bristol Myer Squibb Company, Washington, DC 20004, USA.
Wellman J; Akouos, Inc., a Wholly Owned Subsidiary of Eli Lilly and Company, Boston, MA 02210, USA.
McCombs C; American Society of Gene and Cell Therapy, Waukesha, WI 53186, USA.

Mol Ther Methods Clin Dev ; 29: 513-521, 2023 Jun 08.

Article em En | MEDLINE | ID: mdl-37287748

Palavras-chave

CMS; Medicaid; cell therapy; coverage to label; development pipeline; gene therapy; patient experience; payment policy; time to treatment; value-based payment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article